Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
Lu Ye, Fei Zhou, Dongdong Cheng, Ming Xie, Xiaoli Yan, Yuyu Xue, Qian Yang, Rong Jia, Lili Zhong, Li Yang, Liqun Zou, Na Huang · 2023
Read Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials by Lu Ye, Fei Zhou, Dongdong Cheng, Ming Xie, Xiaoli Yan, Yuyu Xue, Qian Yang, Rong Jia, Lili Zhong, Li Yang, Liqun Zou, Na Huang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10746851.txt.
Description
Lu Ye, Fei Zhou, and a large team of co-authors reviewed trials of drugs that target the CD38 protein in people whose multiple myeloma had come back or stopped responding to care. Their 2023 review pooled randomized trials found in four large databases up to June 2023.
The team compared drug pairs that add the CD38 drugs to standard pairs, looking at how long patients lived without the disease getting worse and how long they lived overall. They also tracked side effects in the blood and in the rest of the body. A step by step check tested whether the pooled proof was firm enough to trust. The review helps doctors weigh gains against harms for a hard to treat blood cancer.
Catalog record
| CREATOR | Lu Ye, Fei Zhou, Dongdong Cheng, Ming Xie, Xiaoli Yan, Yuyu Xue, Qian Yang, Rong Jia, Lili Zhong, Li Yang, Liqun Zou, Na Huang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |